



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



REVIEW ARTICLE

Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects



D. Visca^{a,b,1}, C.W.M. Ong^{c,d,1}, S. Tiberi^{e,f}, R. Centis^g, L. D'Ambrosio^h, B. Chen^c, J. Muellerⁱ, P. Muellerⁱ, R. Duarte^{j,k}, M. Dalcolmo^l, G. Sotgiu^m, G.B. Migliori^{g,*}, D. Golettiⁿ

^a Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

^b Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Varese-Como, Italy

^c Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

^d Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore

^e Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

^f Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom

^g Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy

^h Public Health Consulting Group, Lugano, Switzerland

ⁱ The Mueller Health Foundation, Boston, MA, USA

^j Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

^k Public Health Science and Medical Education Dept, Faculty of Medicine, University of Porto, Porto, Portugal

^l Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

^m Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

ⁿ Translational Research Unit, Epidemiology and Preclinical Research Department, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy

Received 14 December 2020; accepted 15 December 2020

KEYWORDS

COVID-19;
Tuberculosis;
Interaction;
Health services;
Impact;
Rehabilitation

Abstract Evidence is accumulating on the interaction between tuberculosis (TB) and COVID-19.

The aim of the present review is to report the available evidence on the interaction between these two infections. Differences and similarities of TB and COVID-19, their immunological features, diagnostics, epidemiological and clinical characteristics and public health implications are discussed. The key published documents and guidelines on the topic have been reviewed.

Based on the immunological mechanism involved, a shared dysregulation of immune responses in COVID-19 and TB has been found, suggesting a dual risk posed by co-infection worsening COVID-19 severity and favouring TB disease progression.

* Corresponding author at: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy.

E-mail addresses: raquelafduarte@gmail.com (R. Duarte), giovannibattista.migliori@icsmaugeri.it (G.B. Migliori).

¹ Equally contributed.

The available evidence on clinical aspects suggests that COVID-19 happens regardless of TB occurrence either before, during or after an active TB diagnosis. More evidence is required to determine if COVID-19 may reactivate or worsen active TB disease. The role of sequelae and the need for further rehabilitation must be further studied

Similarly, the potential role of drugs prescribed during the initial phase to treat COVID-19 and their interaction with anti-TB drugs require caution. Regarding risk of morbidity and mortality, several risk scores for COVID-19 and independent risk factors for TB have been identified: including, among others, age, poverty, malnutrition and co-morbidities (HIV co-infection, diabetes, etc.). Additional evidence is expected to be provided by the ongoing global TB/COVID-19 study.

© 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The year 2020 will probably be remembered as the 'COVID-19 (coronavirus disease) year'. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for this pandemic emerged in January/February, having originated from China in late 2019.¹⁻³ Although COVID-19 continues to dominate both the scientific literature and the media, other communicable diseases including tuberculosis (TB) should not be neglected.⁴

Much has been written on the potential interactions between COVID-19 and tuberculosis (TB) following the World Health Organisation (WHO) declaration of COVID-19 as a Public Health Emergency of International Concern,⁵ initially based on assumptions, modelling⁶⁻⁸ and scientific evidence.⁹⁻¹³

The view of the WHO,⁷ and the specialized scientific press and newspapers^{14,15} is that an important consequence of the COVID-19 pandemic would be a worsening of the TB epidemic globally, for a variety of reasons, such as additional pressures on health systems by COVID-19 resulting in weakening of the National TB programmes¹⁶ and the potential biological effects of the interaction of the two infections, recalling the concept of 'cursed duet' which in the past was used for TB and HIV.¹⁷

The aim of the present review is to describe the available evidence on the interaction between COVID-19 and TB, starting from differences and similarities, proceeding to describe immunological features, diagnostic implications, epidemiological and clinical characteristics (including impact on mortality) and public health implications (impact on health services).

Methods

We made a rapid and non-systematic search of the literature using the key-words 'COVID-19', 'tuberculosis', 'immunology', 'diagnosis', 'prevention', 'treatment', 'infection control', 'workplace' to identify a minimum set of references from an electronic database (PUBMED), existing guidelines on TB and COVID-19, airborne diseases, and grey literature. This review belongs to the Pulmonology TB series 2021.¹⁸

Differences and similarities between COVID-19 and TB

Recent literature comparing,¹⁹⁻²⁶ COVID-19 and TB are summarised with key similarities and differences in Table 1.

The main difference is that TB is curable, while definite evidence on effective anti-viral agents or other drugs for COVID-19 is still lacking.^{35,36}

Research on new and effective vaccines is ongoing for both diseases: vaccination for COVID-19 has now started while for TB several candidates are under evaluation to replace the old BCG.³⁷

Both COVID-19 and TB have the capacity to stress health systems, they are airborne transmissible diseases, can be diagnosed rapidly (although implementation of rapid testing is not yet available in all settings), they cause stigma and need public awareness and cooperation to allow prevention, diagnosis and treatment to be effective. Although surveillance is able to report on TB and viral diseases separately, in the vast majority of countries the information on COVID-19 is still incomplete and information on TB do not contain many clinical and immunological parameters, which would be useful to better understand the interaction between the two diseases. Moreover COVID-19 pandemic has led to a significant fall in TB notifications.⁹

In terms of funding, although health systems can be considered relatively underfunded even in resource rich countries (a debate is ongoing in these countries on the adequacy of prevention services and on the needed number of intensive care unit beds) human and economic resources for TB are historically sub-optimal at the global level, while resources have been rapidly mobilised against COVID-19 following the wave(s) of the emergency.^{19,20,38}

A long story of prevention and control exists for TB, with the development of: a) national TB control programmes and b) prevention, diagnosis and treatment policies and guidelines in almost all countries of the world (although they are not always correctly implemented). On the COVID-19 side, the policy guidance is under continuous development, following the growing evidence available with the first and subsequent waves.

Table 1 Differences and similarities between tuberculosis and COVID-19.

Specific aspect	COVID-19	TB	Comment
Human exposure	Recent (months)	Ancient (millennia)	COVID-19 was first identified in Wuhan, China in December 2019 and is believed to have likely originated in bats, although the precise origination remains unknown. TB in humans can be traced back to 9000 years ago in Atlit Yam, a city off the coast of Israel. On March 24, 1882, Dr. Robert Koch announced the discovery of <i>Mycobacterium tuberculosis</i> , the bacteria that causes tuberculosis (TB), ²⁷
Epidemiology	Significant burden	Significant burden	Both diseases pose a significant burden. For TB, there are roughly 1.8 billion people infected globally. Additionally, approximately 10 million new cases and 1.5 million deaths annually occur from tuberculosis. ⁷ For COVID-19, there are roughly 56.1 million cases and 1.34 million deaths globally as of November 18 th , 2020 ²⁸
Transmission	Droplet transmission of SARS-CoV-2.	Droplet transmission of <i>M. tuberculosis</i> bacterium.	COVID-19 may also be transmitted via surface contamination, possibly the fecal-oral route, and there may be some aerosol transmission. Transmission occurring from asymptomatic individuals may be less for TB than COVID-19.
Symptoms	– Fever or chills – Cough, shortness of breath or difficulty breathing – Fatigue and headache – Muscle or body aches – New loss of taste or smell – Sore throat, congestion, or runny nose – Nausea, vomiting, or diarrhea – Cancer	– Coughing with mucus or blood – Coughing that lasts more than 2 months – Chest pain – Loss of appetite – Weight loss - Chills, fever, or night sweats – Fatigue – Cancer	COVID-19 poses an additional challenge given that a proportion of spread is from asymptomatic individuals.
Comorbidities Increasing Vulnerability	– Chronic Kidney Disease – Chronic Lung Diseases – Obesity – Heart Conditions – Sickle Cell Disease – Immunocompromised State – Type 2 Diabetes Mellitus	– Chronic Lung Diseases – Smoking – Alcohol Use Disorders - Depression – HIV – Immunocompromised State – Type 2 Diabetes Mellitus	For both diseases, the comorbidities leading to increased vulnerability of the patients are similar.

Table 1 (Continued)

Specific aspect	COVID-19	TB	Comment
Availability of effective vaccine	No (studies ongoing, expected early 2021)	Yes (old BCG vaccine; new candidate vaccines under study)	For tuberculosis, the Bacille Calmette-Guérin (BCG) vaccine is available for newborns and infants and recommended in high TB incidence settings. However, the effectiveness of the BCG vaccine is significantly lower for adults and elderly populations. For COVID-19, vaccine trials are currently ongoing. There appears to be a lack of data regarding the effectiveness of potential COVID-19 vaccines in elderly or immunocompromised individuals.
Other preventive measure	Yes (infection control with hand washing, social distancing, cough etiquette, contact tracing of infected individuals, lock-downs, curfews)	Yes (infection control with administrative, environmental and personal protection measures; contact tracing and treatment of infected individuals)	For COVID-19, personal protection equipment and maintaining physical distance are even more critical given the asymptomatic spread. While mitigation measures (curfews, closing businesses) are not used for TB, they have been necessary to combat COVID-19 in many countries, due to failure of containment measures and rapid community transmission. For both diseases, contact tracing and investigation at the onset is crucial, before community transmission becomes entrenched.
Availability of rapid diagnostics	Yes	Yes	For both diseases, screening symptoms include cough, fever, shortness of breath and nucleic acid amplification tests (NAAT) are recommended as the first test. For TB, sputum tests are used and chest radiography can identify active TB in patients. COVID-19 diagnostic tests use naso or oro-pharyngeal swabs and the use of saliva or sputum is currently being studied.
Availability of cure	No (studies ongoing, support measures used including oxygen and ventilation)	Yes	TB has established curative treatment regimens that include the administration of first line drugs such as rifampicin, isoniazid, ethambutol and pyrazinamide. Drug regimens can be completed at home with regular follow-up visits to the hospital. For COVID-19, trials are currently ongoing and only limited treatments are currently available, including the administration of remdesivir and dexamethasone in severe cases. Approximately 5% experience severe symptoms necessitating intensive care and invasive mechanical ventilation and ~20% are hospitalized. ²⁹

Table 1 (Continued)

Specific aspect	COVID-19	TB	Comment
Limitations of Current Treatments	Trials are currently ongoing and little is known about potential limitations due to lack of treatment options.	There is an increase in limitations due to the rise of resistant strains to rifampicin and isoniazid (MDR) and with additional resistances (XDR).	For TB, there are significant negative adverse events of medication leading to higher rates of non-compliance or early termination of the treatment plan. Additionally, treatment durations are lengthy and can last from 6 months to 2 years. For COVID-19, treatment duration is currently unknown due to the lack of available treatment plans. There are some compassionate use treatment options available to temporarily treat symptoms, however, no direct antiviral treatment is available.
Agreed-upon case-definition	Yes (still under development)	Yes (well established)	The case definition and associated criteria for COVID-19 classification continues to be updated and the latest interim case definition was approved on August 5 th , 2020 by the CDC. ³⁰ For tb, the case definition has been well established by the CDC since 2009 ³¹ WHO has regularly update the full set of definitions to manage TB. ⁷
Potentiality for stigma	Yes	Yes	The stigma of tuberculosis is a perceived risk of transmission from TB-infected individuals to susceptible community members. Additionally, TB is often stigmatized because of its associations with HIV, poverty, low social class, and malnutrition. For Covid-19, numerous forms of stigma and discrimination have been reported, including xenophobia directed at people thought to be responsible for bringing COVID-19 into countries, attacks on health-care workers and verbal and physical abuse towards people who have recovered from COVID-19.
Policy development	Rapid	Slow	Risk communication and rapid implementation of travel policies and quarantine restrictions are a large part of the COVID-19 mitigation efforts. While policy development for TB has been slow, countries have been working to adopt and implement national TB strategies and programs, however, a large gap between policy and practice continues to exist due to financial and human resource constraints.

Table 1 (Continued)

Specific aspect	COVID-19	TB	Comment
Resource mobilisation	Rapid	Slow	For Covid-19, resource mobilisation has occurred rapidly and through effective multi-sectoral engagement. Resource mobilisation for tuberculosis has been slow and there continues to be an annual funding deficit for TB research and development of more than \$1.6 billion, a shortfall that is exacerbated by a lack of market incentives within the pharmaceutical industry. ³²
Economic impact	Huge (rapid)	Huge (slow)	The economic burden of TB between 2006 and 2015 for twenty-two high-burden countries is estimated be about \$3.4 trillion. ³³
Stress on health systems	Huge (rapid)	Huge (slow)	In May 2020, the Asian Development Bank announced that the COVID-19 pandemic could cost the global economy between \$5.8 and \$8.8 trillion. ³⁴
Availability of data	Incomplete	Simple and historically complete	The Covid-19 pandemic put health systems under immense pressure and often stretches hospitals and healthcare providers beyond capacity due to lack of infrastructure and equipment (hospital beds, ventilators) and staff and skills (overworked healthcare workers, lack of intubation skills). An increase in tuberculosis cases in high-burden counties puts additional pressure on already resource strained health systems that are already facing additional epidemics such as HIV. Additionally, new and existing health systems across the globe need to adapt to the rise of resistant forms of tuberculosis to provide better and affordable care.
			TB is a slow-moving epidemic and quarterly data is available at the national level. Due to the rapid spread, COVID-19 requires daily data updates, which is often incomplete or inaccurate. Availability and accessibility of surveillance data is crucial for both TB and COVID-19 responses to follow and respond quickly to the hot spots.

COVID-19: coronavirus disease; TB: tuberculosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; BCG: Bacille Calmette-Guérin; NAAT: nucleic acid amplification tests; MDR: multi-drug resistant; XDR: extensively drug-resistant; CDC: Centers for Disease Control and Prevention.

Biological interactions

COVID-19 is a communicable disease caused by SARS-CoV-2, a member of the beta Coronaviridae family, which also includes SARS-CoV-1 (severe acute respiratory syndrome coronavirus 1) and MERS-CoV (Middle East respiratory syndrome coronavirus).³⁹ The SARS-CoV-2 genome is up to 80% similar to SARS-CoV-1 and 50% similar to MERS-CoV.^{39,40} The coronavirus spike (S) glycoprotein, common to all these viruses, belongs to the class-I viral fusion proteins and upregulates and engages angiotensin-converting enzyme 2 (ACE2) as the entry receptor into humans.^{41,42} However, not all people exposed to SARS-CoV-2 are infected and not all infected patients develop severe respiratory illness.³ Accumulating evidence indicates that COVID-19 can be roughly divided into three stages: *stage 1*, an asymptomatic incubation period with or without detectable virus; *stage 2*, non-severe symptomatic period with the presence of virus; *stage 3*, severe respiratory symptomatic stage with high viral load⁴³ and important immune response with subsequent deterioration of the lung damage, respiratory failure (that may require invasive-mechanical ventilation) and multi-organ dysfunction.^{44–47} (Fig. 1)

It has been shown that a broad and coordinated SARS-CoV-2 antigen-specific adaptive immune responses (ADIMs) among CD4, CD8 and B cells are associated with lower COVID-19 disease severity, while absent or minimal adaptive immunity is associated with more severe COVID-19 disease. In particular SARS-CoV-2-specific CD4 + T cells are associated with protective immune responses.⁴⁸ Significant redundancy or compensation may exist between the protective actions of neutralizing antibodies, SARS-CoV-2-specific CD4 T cells, and SARS-CoV-2-specific CD8 T cells.⁴⁸

CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate granulocyte-macrophage colony stimulating factor (GM-CSF). The cytokine environment induces CD14 + CD16 + monocytes with high expression of IL-6 and accelerates inflammation. Also, over-activation of T cells, manifested by the increase in Th17 and high cytotoxicity of CD8 + T cells in the peripheral blood of a patient with severe COVID-19, have been reported.⁴⁹ Although the pathophysiology of SARS-CoV-2 is not yet fully understood, it seems there are similarities with that of SARS-CoV-1.⁵⁰

Certain therapeutic interventions are under evaluation for the incubation and early stages of SARS-CoV-2 infection; these include convalescent plasma, pegylated IFN α (Interferon alpha), zinc, vitamin B3 and/or specific antivirals like remdesivir and Regeneron's casirivimab/imdevimab antibody cocktail and bamlanivimab (Eli Lilly), some of which have already US Food and Drug Administration Emergency Authorization.^{51–53} However, the treatment with hydroxychloroquine and lopinivir/ritonavir has not been significantly associated with differences in hospital mortality.^{54,55}

For patients with severe COVID-19, mostly immunosuppressive therapeutic options have been proposed, with dexamethasone being recommended for use and others currently being evaluated including HAS2 (Hyaluronan Synthase 2) inhibitors as well as activated MSCs (mesenchymal stromal /stem cells).^{44,56,57} (Fig. 1). Lung and tissue damage, which can occur with hypoxia even in TB,⁵⁸ have also been

described as sequelae to COVID-19 infection,⁵⁹ as well as thrombosis and pulmonary emboli.⁴⁷

Although viral respiratory infections and TB impair the host's immune responses little evidence is available about co-infection of SARS-CoV-2 and *Mycobacterium tuberculosis*. TB status might play a role in the development of COVID-19 infection and exacerbation of the course of the disease for the co-infected population considering cases studied in China and India⁶⁰ and the evidence provided by a study performed on a systematic transcriptomic evaluation of immune signatures associated with COVID-19 clinical severity and the spectrum of asymptomatic and symptomatic TB.¹⁷ In particular the results of this study performed on the transcriptomic evaluation of whole blood (WB), peripheral blood mononuclear cell (PBMC) and bronchoalveolar lavage fluid (BALF) signatures suggest that subclinical and active TB (ATB) increase the risk of severe COVID-19 disease, due to increased abundance of circulating myeloid subpopulations which are also found in the lungs of severe COVID-19 patients.¹⁷ The increased IFN production and the type I and III IFN responses signatures are significantly upregulated in severe disease in both COVID-19⁶¹ and TB⁶² and may lead to disease progression and severe/fatal outcomes. COVID-19 may therefore pose the biggest threat to ending the TB epidemic.⁶

Also, the use of immunosuppressive drugs in severe and critical COVID-19 patients, although done for a limited period of time, may result in increased likelihood of active TB caused by reactivation or new infection of *M. tuberculosis*^{63,64} even in post-pandemic times.

Diagnostic tests

A range of diagnostic tests is available for both TB and COVID-19. For both pathogens, nucleic acid detection tests, and antigen-based tests are available while culture-based and smear methods apply to *Mycobacterium tuberculosis* and serology for SARS-CoV-2 (Table 2).

The WHO has described the ASSURED criteria (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable to end-users), relevant to both *Mycobacterium tuberculosis* and SARS-Cov-2, to identify the most appropriate diagnostic tests for most settings.⁷⁷ However, a key limitation to all available tests, independent of the pathogen, is the inability to promptly declare if the pathogen is viable and infectious⁷⁸ For SARS-CoV-2, the virus requires live eukaryotic cells to replicate, with a minimum turn-around-time of one week to determine viability. For *Mycobacterium tuberculosis*, culture results to determine viability require a minimum of 6 weeks. Even in this age of state-of-the-art technology, rapid information on the state of infectiousness of these two pathogens remains elusive. An interesting experimental approach to evaluate SARS-CoV2-specific response in the whole blood has been recently reported^{79,80}. It describes that SARS-CoV2-specific response is detectable in the whole blood and is present during the acute phase⁷⁹ as well as in the convalescents.⁸⁰

Table 2 Diagnostic tests for *M. tuberculosis* and SARS-CoV-2.

Pathogen	<i>Mycobacterium tuberculosis</i>				SARS-CoV-2		
Diagnostic method	Culture	Smear microscopy	NAAT	Antigen-based test	NAAT	Antigen-based test	Serology
Example of test	BD BACTEC MGIT, solid culture	ZN stain/ AR stain	Xpert MTB/RIF Ultra assay	Loopamp MTBC detection kit	PCR/RT-PCR	See FDA website ⁶⁵	See FDA website ⁶⁵
Sensitivity	Gold standard	Up to 84% ⁶⁶	Up to 91% ⁶⁷	64-80% ⁶⁸	Up to 98% for nasopharyngeal swab ⁶⁹ Up to 91% for saliva ⁶⁹	84.0% - 97.6% ⁷⁰	Varying ⁷¹
Specificity	Gold standard	98-99% ⁶⁶	Up to 100% ⁶⁷	95-99% ⁶⁸	Gold standard	100% ⁷⁰	Varying ⁷¹
Rapidness (time to result)	1–2 weeks (liquid) 3–8 weeks (solid)	≤ 1 day ⁷²	< 2 h ⁷³	60 min ⁶⁸	Ranges from 15 min to >2 days ⁷⁰	15 min ⁷⁰	< 30 min – few hours ⁷¹
Sample preparation	Multiple steps	Multiple steps	Three steps	Multiple steps	Multiple steps	Minimal to none	Multiple steps
Equipment	Culture incubator, biosafety cabinet	Microscope	GeneXpert instrument	Heating block	Thermal cycler, heating block	Digital telecommunication	ELISA kit and microplate reader, or lateral flow assay strip
Deliverable (minimum laboratory level)	Intermediate	Peripheral	Peripheral	Peripheral	Intermediate	Peripheral/POC	POC - Intermediate
Affordability	US\$ 1.63-45.96 ⁷⁴	ZN: US\$ 1.16–2.54 AR: 1.08-1.64 ⁷⁴	US\$ 9.98 ⁷⁵	US\$ 6.04 ⁷⁸	\$1.21-\$4.39/sample in reagent costs for saliva ⁷⁶ Instrument charges vary	< US \$20	US \$20–100

AR, Auramine-rhodamine; NAAT, nucleic acid amplification test; PCR, polymerase chain reaction; POC, point-of-care; RT-PCR, real-time polymerase chain reaction; TB-LAMP, tuberculosis loop-mediated isothermal amplification;; ZN, Ziehl-Neelsen.




Fig. 1 Schematic representation of the progression of COVID-19 infection and potential adjuvant interventions. IFNα: Interferon alpha; IV: Intravenous; HAS2: Hyaluronan Synthase 2. Created with [BioRender.com](https://www.biorender.com).

Epidemiological and clinical presentation of COVID-19 with TB infection

In a first meta-analysis of six studies from China on a few patients,⁸¹ the TB prevalence among COVID-19 patients ranged between 0.47 to 4.47%. The TB prevalence was higher among patients with severe COVID-19 than in non-severe ones (1.47%, 10/680 vs 0.59%, 10/1703; OR: 2.1; $P = 0.24$).

In a cohort from eight countries (Belgium, Brazil, France, Italy, Russia, Singapore, Spain and Switzerland)¹¹ TB and COVID-19 were studied in 49 patients during the initial wave of the pandemic. TB was diagnosed before COVID-19 in 26 patients (53.0%), COVID-19 was diagnosed before TB in 14 ones (28.5%) while the diagnosis was concomitant in 9 patients (18.3%) (within the same week). Forty-two patients (85.7%) had active TB while 7 (14.3%) suffered post-cure TB sequelae. The authors concluded the following:

- 1) COVID-19 can occur before, simultaneously or after the diagnosis of TB;
- 2) The role of COVID-19 in boosting the development of active TB is yet to be established;
- 3) The role of TB sequelae in COVID-19 evolution is also unclear, potentially being a risk factor for worsening outcomes;
- 4) Further studies are needed to enable analysis of interactions and determinants of outcomes in patients with both diseases.

These findings have been confirmed by a similar study conducted in India.⁸²

In an interesting clinical study conducted in a reference TB centre in Northern Italy, the Sondalo Hospital,¹³ detection of Sars-Cov2 was made in 20 patients (the majority being young migrants without co-morbidities) following nosocomial transmission. All patients received hydroxy-chloroquine and no antiviral drug was administered, with oxygen administered to 4 patients at admission and 3 during their hospital stay. A single elderly patient with advanced pulmonary TB and cachexia developed COVID-19 pneumonia and died 6 days after admission. The other 19 patients had a good clinical outcome. TB lesions at chest radiography did not worsen and only 4 patients had signs of newly developed pneumonia.

The data reported suggest the following:

- 1 Low rate of clinical and radiological deterioration may be associated to young age of most patients, low frequency of co-morbidities, good quality of healthcare service
- 2 Impact of COVID-19 on active TB appears to be manageable with proper care. Rigorous infection control and personal protection devices are crucial to prevent the risk of in-hospital transmission.⁸³

Prognosis and mortality resulting from COVID-19 and TB interaction

In the meta-analysis mentioned above⁸¹ the risk of TB death was 1.4 times higher in COVID-19 patients. The findings of a

recent study¹² on 69 patients from 8 countries suggest the following:

- 1) The case fatality rate in the overall cohort was 11.6% (8/69); 14.3% (7/49) in the 8 countries study¹¹ and 5% (1/20, the single old patient with comorbidities) in the Sondalo Hospital study.¹³
- 2) Mortality is likely to occur in elderly patients with comorbidities;
- 3) TB might not be a major determinant of mortality;
- 4) Migrants experienced lower mortality, probably due to their younger age and lower number of co-morbidities. However, the authors commented that in patients with severe TB and/or with a disease caused by resistant strains of *Mycobacterium tuberculosis*, a higher mortality rate can be expected also in younger individuals.

In a recent modelling study based on data from the Philippines,⁸⁴ the risk of death in TB patients co-infected with COVID-19 was 2.17 times higher than in non COVID-19 ones, with a shorter time-to-death. The risk of recovery in these patients was 25% lower than in non COVID-19 ones, with longer time-to-recovery.

A study from South Africa⁸⁵ showed that while HIV-TB co-infection doubled the risk of death of TB patients compared to HIV-uninfected individuals, TB (both drug-susceptible and drug resistant) increased the hazard of COVID-19 death of 2.7. A lower increase (1.51) was reported in those with previous TB.

A global study on TB and COVID patients, coordinated by the Global Tuberculosis Network (GTN) and supported by the World Health Organization (WHO) is going on at present to improve the description of the interaction between the two diseases. As of October 13th 2020, 36 Countries/Regions joined the global study, with 132 Centres from 27 Countries/Regions having already provided data for 597 individual patients.⁸⁶ The primary objective of the study is to describe the characteristics of patients with COVID-19 and TB (current or past), including diagnostic tests and prescribed therapies. The secondary objectives are: 1. To evaluate the logistic and organizational feasibility of a global repository for patients with COVID-19 and TB and 2) to describe the clinical outcomes (outcomes of COVID-19 disease, as well as interim and final treatment outcomes of TB patients).⁸⁶

The GTN suggested several priority research questions to be answered with this global a study and others ones.

They include:

- 1 Does COVID-19 increase the risk of developing TB disease in individuals with TB infection?
- 2 What is the COVID-19 attributable risk on TB mortality?
- 3 What are the other determinants of mortality in TB–COVID-19 co-infected patients?
- 4 Is BCG vaccination protective for COVID-19?⁸⁷
- 5 Do TB/COVID-19 co-infected patients require different management? (or in other words, which additional services are needed for these patients?)
- 6 What impact will COVID-19 have on TB services over the coming years, considering also the increasing effects of its second wave?

- 7 Are patients with post-TB sequelae a higher risk group for COVID? Do they suffer increased mortality or delayed cure? Do these patients require specific rehabilitation services?

According to recent studies, a high proportion of cases with post-TB treatment sequelae suffer from lung function impairment and poor Quality of Life (QoL). Preliminary data suggest that pulmonary rehabilitation is effective in patients with a previous history of TB.^{88–91}

In addition, it has been well described that severe acute respiratory syndrome is the dominant finding of the acute phase of COVID-19 infection whilst functional impairment of patients surviving the COVID-19 acute phase has been poorly described. Recent studies suggested that early, post-hospitalization rehabilitative interventions should be recommended.^{92–94}

Impact of the COVID-19 pandemic on TB services

Few studies are available on the potential interaction of COVID-19 on the TB health services.^{9,15}

The GTN global study⁹ evaluated patient attendances in TB health care units in 33 centres from 16 countries comparing the volume of TB-related healthcare activities in the first 4 months of the COVID-19 pandemic (January–April 2020) to the same period in 2019.⁹ The majority of the centres experienced reductions during their national lockdowns in the first 4 months of 2020, in TB-related hospital discharges, of newly diagnosed cases of active TB, of the total active TB outpatient visits, and of the new latent TB infections diagnosed (and related outpatient visits). In some centres, personnel initially attributed for TB service provision were re-prioritised to COVID-19. In addition, the decreased attendance to TB clinics was associated with patient fear of exposure to COVID-19 in the community or with disruptions of the services or struggle in accessing health services during lockdown. Conversely, national lockdowns favoured the increased use of telemedicine. In the TB centres surveyed in Australia, Russia, India, and the United Kingdom, telehealth service use increased.

A study carried out in Sierra Leone¹⁰ compared the number of patients assessed for presumptive TB and the number of those confirmed sputum smear positive in the first 4 months of 2020 with the number of cases reported in 2018 and 2019. The results show a significant drop of confirmed TB cases. Furthermore, the number of presumptive TB decreased in March/April 2020, with no treatment supervised nor cases of TB/COVID-19 coinfection or childhood TB detected in April 2020. The study shows the indirect impact of COVID-19 on TB care in a low-resource high TB-burden setting. The study suggests that Africa needs economic and technology support to strengthen its response to COVID-19 pandemic. Otherwise, all results achieved in recent years in the fight against TB may be lost.

Similar findings have been observed in Brazil,⁹⁵ China,⁹⁶ India,^{7,97} Iran,⁹⁸ Nigeria⁹⁹ and United States (migrants).¹⁰⁰ A similar experience was reported on children in South Africa.¹⁰¹ In Korea, on the contrary, the impact of COVID-19 on the performances of the TB private sector project (PPM) was not observed.¹⁰² Repeat lockdowns of varying degrees

are reported in countries which have recurrent COVID-19 waves, and severe consequences to TB services are therefore expected.²⁶

Conclusions

COVID-19 causes a spectrum of host immunological responses with asymptomatic individuals to severe cytokine-storm events that may be fatal. Immunosuppression including steroids used to treat COVID-19 may in future result in TB reactivation. Gold standard diagnostic tests for COVID-19 are PCR, and culture-based methods for TB, but an ideal point-of-care tests that can promptly inform if an individual is actively infectious with TB remains elusive.

COVID-19 can occur at any time during a patient's TB journey, with worse outcomes for patients affected by active pulmonary TB disease. More evidence is needed to understand the potential of COVID-19 to favor reactivation of an existing TB infection. The aspecific signs and symptoms common to COVID-19 and TB may facilitate a rapid access to imaging services (chest radiography and/or computerized tomography) which may manifest signs of a pre-existing TB.

Available data is insufficient to understand the potential effect of COVID-19 on the TB patients' treatment outcome,^{11,12,86} as in existing series the majority of these patients are still undergoing treatment.

Based on the information available so far, the main determinants of mortality for COVID-19 are age and comorbidities, including HIV co-infection, poverty, diabetes and malnutrition, all of these also have an impact on TB mortality.

We need higher quality prospective studies to really answer the main research questions raised. In the meantime patients who had or have active TB especially people living with HIV co-infection should do their utmost to avoid getting COVID-19 and should be offered suitable vaccination when possible.

Declarations of interest

None.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Acknowledgments

The Authors wish to thank Dr Martin van den Boom (World Health Organization Regional Office for Europe) for his useful comments on the manuscript.

The article is part of the scientific activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA).

References

- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–42, <http://dx.doi.org/10.1001/jama.2020.2648>.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507–13, [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7).
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20, <http://dx.doi.org/10.1056/NEJMoa2002032>.
- Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. *Int J Tuberc Lung Dis*. 2020;24(5):547–8.
- World Health Organization. Statement on the second meeting of the International Health Regulations. Geneva, Switzerland: Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2005, 30 January 2020, Available at: [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)). Accessed 9 December, 2020.
- Stop TB Partnership, Imperial College, Avenir Health, Johns Hopkins University, and USAID. The Potential Impact of the COVID-19 Response on Tuberculosis in High-Burden Countries: A Modelling Analysis. Available at: http://www.stoptb.org/assets/documents/news/Modeling%20Report.1%20May%202020_FINAL.pdf. Accessed 9 December, 2020.
- World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available at: <https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf>. Accessed 9 December, 2020.
- Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. *EClinicalMedicine*. 2020;28:100603, <http://dx.doi.org/10.1016/j.eclinm.2020.100603>.
- Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. *Emerg Infect Dis*. 2020;26(11):2709–12, <http://dx.doi.org/10.3201/eid2611.203163>.
- Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone. *Pulmonology*. 2021;27(jan-feb (1)), <http://dx.doi.org/10.1016/j.pulmoe.2020.05.013>, in press.
- Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J*. 2020;56(1):2001398, <http://dx.doi.org/10.1183/13993003.01398-2020>.
- Motta I, Centis R, D'Ambrosio L, García-García JM, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology*. 2020;26(Jul-Aug (4)):233–40, <http://dx.doi.org/10.1016/j.pulmoe.2020.05.002>.

13. Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. *Eur Respir J*. 2020;56(1):2001708, <http://dx.doi.org/10.1183/13993003.01708-2020>.
14. Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. *Science*. 2020;369(6502):366–8, <http://dx.doi.org/10.1126/science.abd1072>.
15. Mandavilli A. 'The biggest monster' is spreading. And it's not the coronavirus. *The New York Times*; 2020, 03 Aug Available at: <https://www.nytimes.com/2020/08/03/health/coronavirus-tuberculosis-aids-malaria.html>. Accessed: 9 December 2020.
16. Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (Waidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). *Eur Respir J*. 2020;56(4):2001727, <http://dx.doi.org/10.1183/13993003.01727-2020>.
17. Sheerin D, Abhimanyu Wang X, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. *medRxiv*. 2020;(Nov), <http://dx.doi.org/10.1101/2020.11.25.20236646>, 2020.11.25.20236646.
18. Migliori GB, Tiberi S, García-Basteiro AL, Duarte R. Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. *Pulmonology*. 2020;(Nov), <http://dx.doi.org/10.1016/j.pulmoe.2020.10.005>. S2531-0437(20)30220-30228.
19. Dara M, Sotgiu G, Reichler MR, Chiang CY, Chee CBE, Migliori GB. New diseases and old threats: lessons from tuberculosis for the COVID-19 response. *Int J Tuberc Lung Dis*. 2020;24(5):544–5.
20. Alagna R, Besozzi G, Codecasa LR, Gori A, Migliori GB, Raviglione M, et al. Celebrating World Tuberculosis Day at the time of COVID-19. *Eur Respir J*. 2020;55(4):2000650, <http://dx.doi.org/10.1183/13993003.00650-2020>.
21. Fatima R, Yaqoob A. In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes. *Int J Tuberc Lung Dis*. 2020;24(11):1227–8, <http://dx.doi.org/10.5588/ijtld.20.0571>.
22. Zhou S, Van Staden Q, Toska E. Resource reprioritisation amid competing health risks for TB and COVID-19. *Int J Tuberc Lung Dis*. 2020;24(11):1215–6, <http://dx.doi.org/10.5588/ijtld.20.0566>.
23. Kadota JL, Reza TF, Nalugwa T, Kityamuwesi A, Nanyunja G, Kiwanuka N, et al. Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic. *Int J Tuberc Lung Dis*. 2020;24(11):1212–4, <http://dx.doi.org/10.5588/ijtld.20.0626>.
24. van der Walt M, Keddy KH. How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease. *Int J Tuberc Lung Dis*. 2020;24(9):978–80, <http://dx.doi.org/10.5588/ijtld.20.0454>.
25. Echeverría G, Espinoza W, de Waard JH. How TB and COVID-19 compare: an opportunity to integrate both control programmes. *Int J Tuberc Lung Dis*. 2020;24(9):971–4, <http://dx.doi.org/10.5588/ijtld.20.0417>.
26. Keddy KH, Migliori GB, Van Der Walt M. Developing health policies in patients presenting with SARS-CoV-2: consider tuberculosis. *Lancet Glob Health*. 2020;8(11):e1357–8, [http://dx.doi.org/10.1016/S2214-109X\(20\)30413-7](http://dx.doi.org/10.1016/S2214-109X(20)30413-7).
27. Lodenkemper R, Murray JF, Gradmann C, Hopewell PC, Kato-Maeda M. History of tuberculosis. In: Migliori GB, Bothamley G, Duarte R, Rendon A, editors. *Tuberculosis*. Sheffield: European Respiratory Society; 2018. p. 8–27, <http://dx.doi.org/10.1183/2312508X.10020617>.
28. Pettersson H, Manley B, Hernandez S. Tracking Coronavirus' Global Spread. *CNN, Cable News Network*; 2020, 19 Nov. Available at: www.cnn.com/interactive/2020/health/coronavirus-maps-and-cases/. Accessed 9 December 2020.
29. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324(8):782–93, <http://dx.doi.org/10.1001/jama.2020.12839>.
30. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5, 2020. Centers for Disease Control and Prevention; 2020, 6 Aug. Available at: www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/. Accessed 9 December 2020.
31. Centers for Disease Control and Prevention. Tuberculosis (TB) (*Mycobacterium Tuberculosis*) 2009 Case Definition. Centers for Disease Control and Prevention; 2009. Available at: www.cdc.gov/nndss/conditions/tuberculosis/case-definition/2009/. Accessed: 9 December 2020.
32. World Health Organization, The Global Fund. Information note: TB financing and funding gaps in 118 countries eligible for Global Fund support. World Health Organization and the Global Fund; 2013. Available at: www.who.int/tb/WHO_GF_TB_financing_factsheet.pdf?ua=1. Accessed 9 December 2020.
33. Laxminarayan R, Klein EY, Darley S, Adeyi O. Global Investments In TB Control: Economic Benefits. *Health Affairs*. 2009;28(51):w730–42, <http://dx.doi.org/10.1377/hlthaff.28.4.w730>.
34. Dennis MJ. The impact of COVID-19 on the world economy and higher education. *Enrollment Management Report*. 2020;24:3, <http://dx.doi.org/10.1002/emt.30720>.
35. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2020;(Dec), <http://dx.doi.org/10.1056/NEJMoa2023184>.
36. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. *Drugs*. 2020;80(18):1929–46, <http://dx.doi.org/10.1007/s40265-020-01421-w>.
37. Afkhami S, Villela AD, D'Agostino MR, Jeyanthan M, Gillgrass A, Xing Z. Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis. *Front Immunol*. 2020;11:557809, <http://dx.doi.org/10.3389/fimmu.2020.557809>.
38. Singla R, Raghu B, Gupta A, Caminero JA, Sethi P, Tayal D, et al. Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room. *Pulmonology*. 2021;27(1):35–42, <http://dx.doi.org/10.1016/j.pulmoe.2020.02.002>, in press.
39. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395(10224):565–74, [http://dx.doi.org/10.1016/S0140-6736\(20\)30251-8](http://dx.doi.org/10.1016/S0140-6736(20)30251-8).
40. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respi-

- ratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5(4):536–44, <http://dx.doi.org/10.1038/s41564-020-0695-z>.
41. Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. *Proc Natl Acad Sci U S A.* 2014;111(42):15214–9, <http://dx.doi.org/10.1073/pnas.1407087111>.
 42. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181(2), <http://dx.doi.org/10.1016/j.cell.2020.02.052>, 271–280.e8.
 43. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–9, <http://dx.doi.org/10.1001/jama.2020.1585>.
 44. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020;395(10229):1033–4, [http://dx.doi.org/10.1016/S0140-6736\(20\)30628-0](http://dx.doi.org/10.1016/S0140-6736(20)30628-0).
 45. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis.* 2020;71(15):769–77, <http://dx.doi.org/10.1093/cid/ciaa272>.
 46. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature.* 2020;584(7821):463–9, <http://dx.doi.org/10.1038/s41586-020-2588-y>.
 47. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, et al. Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. *J Infect Dis.* 2020;222(11):1807–15, <http://dx.doi.org/10.1093/infdis/jiaa578>.
 48. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell.* 2020;183(4), <http://dx.doi.org/10.1016/j.cell.2020.09.038>, 996–1012.e19.
 49. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020;8(4):420–2, [http://dx.doi.org/10.1016/S2213-2600\(20\)30076-X](http://dx.doi.org/10.1016/S2213-2600(20)30076-X).
 50. Crisan-Dabija R, Grigorescu C, Pavel CA, Artene B, Popa IV, Cernomaz A, et al. Tuberculosis and COVID-19: Lessons from the past viral outbreaks and possible future outcomes. *Can Respir J.* 2020;2020:1401053, <http://dx.doi.org/10.1155/2020/1401053>.
 51. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269–71, <http://dx.doi.org/10.1038/s41422-020-0282-0>.
 52. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med.* 2020;382(10):929–36, <http://dx.doi.org/10.1056/NEJMoa2001191>.
 53. Press Release Regeneron. Regeneron's Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization; 2020. November 21, Available at: <https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive>. Accessed 9 December 2020.
 54. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA.* 2020;323(24):2493–502, <http://dx.doi.org/10.1001/jama.2020.8630>.
 55. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoret C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. *Pulmonology.* 2021;27(1), <http://dx.doi.org/10.1016/j.pulmoe.2020.07.003>, in press.
 56. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. *J Infect.* 2020;81(2):318–56, <http://dx.doi.org/10.1016/j.jinf.2020.04.017>.
 57. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. *J Infect.* 2020;81(4):647–79, <http://dx.doi.org/10.1016/j.jinf.2020.06.052>.
 58. Ong CWM, Fox K, Ettorre A, Elkington PT, Friedland JS. Hypoxia increases neutrophil-driven matrix destruction after exposure to Mycobacterium tuberculosis. *Sci Rep.* 2018;8(1):11475, <http://dx.doi.org/10.1038/s41598-018-29659-1>.
 59. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Grifanti L, Falfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *medRxiv.* 2020, <http://dx.doi.org/10.1101/2020.10.15.20205054>, 2020.10.15.20205054.
 60. Yasri S, Wiwanitkit V. Tuberculosis and novel Wuhan coronavirus infection: Pathological interrelationship. *Indian J Tuberc.* 2020;67(2):264, <http://dx.doi.org/10.1016/j.ijtb.2020.02.004>.
 61. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. *Nat Rev Immunol.* 2020;20(7):397–8.
 62. Cliff JM, Kaufmann SHE, McShane H, van Helden P, O'Garra A. The human immune response to tuberculosis and its treatment: a view from the blood. *Immunol Rev.* 2015;264(1):88–102.
 63. Yang H, Lu S. COVID-19 and Tuberculosis. *J Transl Int Med.* 2020;8(2):59–65, <http://dx.doi.org/10.2478/jtim-2020-0010>.
 64. Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2016;15(5):11–34, <http://dx.doi.org/10.1080/14740338.2016.1240783>.
 65. Food and Drug Administration. In Vitro Diagnostics EUAs; 2020. Available at: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-antigen>. Accessed 9 December 2020.
 66. World Health Organization. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement. WHO/HTM/TB/2011.8. Geneva: World Health Organization; 2011. Available at: https://apps.who.int/iris/bitstream/handle/10665/44602/9789241501613_eng.pdf;jsessionid=DA5CF0944176120288D5755A7D702C86?sequence=1. Accessed 9 December 2020.
 67. Zhang M, Xue M, He JQ. Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: A preliminary systematic review and meta-analysis. *Int J Infect Dis.* 2020;90:35–45.
 68. World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. WHO/HTM/TB/2016.11. Geneva: World Health Organization; 2016. Available at: <https://apps.who.int/iris/bitstream/handle/10665/249154/>

- 9789241511186-eng.pdf?sequence=1. Accessed 9 December 2020.
69. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy A, et al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. *Front Med (Lausanne)*. 2020;7:465, <http://dx.doi.org/10.3389/fmed.2020.00465>.
 70. Centers for Disease Control and Prevention. Interim Guidance for Rapid Antigen Testing for SARS-CoV-2; 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html>. Accessed 9 December 2020.
 71. Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing; 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>. Accessed 9 December 2020.
 72. World Health Organization. Same-day diagnosis of tuberculosis by microscopy: policy statement. WHO/HTM/TB/2011.7. Geneva: World Health Organization; 2011. Available at: <https://apps.who.int/iris/bitstream/handle/10665/44603/9789241501606-eng.pdf?sequence=1>. Accessed 9 December 2020.
 73. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system: policy statement. WHO/HTM/TB/2011.4. Geneva: World Health Organization; 2011. Available at: <https://apps.who.int/iris/bitstream/handle/10665/44586/9789241501545-eng.pdf?sequence=1&isAllowed=y>. Accessed 9 December 2020.
 74. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A Systematic Review of Reported Cost for Smear and Culture Tests during Multidrug-Resistant Tuberculosis Treatment. *PLoS One*. 2013;8(2):e56074, <http://dx.doi.org/10.1371/journal.pone.0056074>.
 75. Stop TB Partnership. Global Drug Facility Diagnostics Catalog October 2019; 2019. Geneva, Switzerland. Available at: <http://www.stoptb.org/assets/documents/about/cb/meetings/32/32-09%20Global%20Drug%20Facility/Resources/32-9-2.5.2%20Stop%20TB%20Global%20Drug%20Facility%20Diagnostics%20Catalog.pdf>. Accessed 9 December 2020.
 76. Vogels CBF, Watkins AE, Harden CA, Brackney DB, Shafer J, Wang J, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. *medRxiv*. 2020, <http://dx.doi.org/10.1101/2020.08.03.2016779>, 2020.08.03.20167791.
 77. Kosack CS, Page AL, Klatser PR. A guide to aid the selection of diagnostic tests. *Bull World Health Organ*. 2017;95(9):639–45, <http://dx.doi.org/10.2471/BLT.16.187468>.
 78. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. *N Engl J Med*. 2020;383(22):e120, <http://dx.doi.org/10.1056/NEJMp2025631>.
 79. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Najafi Fard S, Alonzi T, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. *Clin Microbiol Infect*. 2020, <http://dx.doi.org/10.1016/j.cmi.2020.09.051>. S1198-743X(20)30605-4.
 80. Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, et al. Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. *Clin Infect Dis*. 2020, <http://dx.doi.org/10.1093/cid/ciaa1537>, ciaa1537.
 81. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. *J Med Virol*. 2020, <http://dx.doi.org/10.1002/jmv.26311>.
 82. Gupta N, Ish P, Gupta A, Malhotra N, Caminero JA, Singla R, et al. A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis. *Eur Respir J*. 2020;56(5):2003408, <http://dx.doi.org/10.1183/13993003.03408-2020>.
 83. Ippolito M, Vitale F, Accurso G, Iozzo P, Gregoretto C, Giarratano A, et al. Medical masks and Respirators for the Protection of Healthcare Workers from SARS-CoV-2 and other viruses. *Pulmonology*. 2020;26(Jul-Aug (4)):204–12, <http://dx.doi.org/10.1016/j.pulmoe.2020.04.009>.
 84. Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. *Infect Dis (Lond)*. 2020;52(12):902–7, <http://dx.doi.org/10.1080/23744235.2020.1806353>.
 85. Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. *Clin Infect Dis*. 2020, <http://dx.doi.org/10.1093/cid/ciaa1198>, ciaa1198.
 86. TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. *Int J Tuberc Lung Dis*. 2021;25(1), <http://dx.doi.org/10.5588/ijtld.20.0786>, in press.
 87. Joy M, Malavika B, Asirvatham ES, Sudarsanam TD, Jeyaseelan L. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. *Clin Epidemiol Glob Health*. 2020;(Sep), <http://dx.doi.org/10.1016/j.cegh.2020.08.015>.
 88. Visca D, Zampogna E, Sotgiu G, Centis R, Sadari L, D'Ambrosio L, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. *Eur Respir J*. 2019;53(3):1802184, <http://dx.doi.org/10.1183/13993003.02184-2018>.
 89. Visca D, Centis R, Muñoz-Torrico M, Pontali E. Post-tuberculosis sequelae: the need to look beyond treatment outcome. *Int J Tuberc Lung Dis*. 2020;24(8):761–2.
 90. Visca D, Centis R, D'Ambrosio L, Muñoz-Torrico M, Chakaya JM, Tiberi S, et al. The need for pulmonary rehabilitation following tuberculosis treatment. *Int J Tuberc Lung Dis*. 2020;24(7):720–2.
 91. Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, Torre-Bouscolet L, Salazar-Lezama MA, Villarreal-Velarde H, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2020;24(7):700–5.
 92. Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. *Eur Respir J*. 2020;56(4):2002096, <http://dx.doi.org/10.1183/13993003.02096-2020>.
 93. Vitacca M, Carone M, Clini EM, Paneroni M, Lazzeri M, Lanza A, et al. ITS - AIPO, the ARIR and the SIP/IRS Joint Statement on the Role of Respiratory Rehabilitation in the COVID-19 Crisis: The Italian Position Paper. *Respiration*. 2020;99(6):493–9, <http://dx.doi.org/10.1159/000508399>.
 94. Zampogna E, Migliori GB, Centis R, Cherubino F, Facchetti C, Feci D, et al. Functional impairment during post-acute COVID-19 phase: preliminary finding in 56 patients. *Pulmonology*. 2020, in press.
 95. de Souza CDF, Coutinho HS, Costa MM, Magalhães MAFM, Carmo RF. Impact of COVID-19 on TB diagnosis in Northeastern Brazil. *Int J Tuberc Lung Dis*. 2020;24(11):1220–2, <http://dx.doi.org/10.5588/ijtld.20.0661>.
 96. Wu Z, Chen J, Xia Z, Pan Q, Yuan Z, Zhang W, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai. *China. Int J Tuberc Lung Dis*. 2020;24(10):1122–4, <http://dx.doi.org/10.5588/ijtld.20.0539>.
 97. Meneguim AC, Rebello L, Das M, Ravi S, Mathur T, Mankar S, et al. Adapting TB services during the COVID-19 pandemic in

- Mumbai, India. *Int J Tuberc Lung Dis.* 2020;24(10):1119–21, <http://dx.doi.org/10.5588/ijtld.20.0537>.
98. Shahriarirad R, Fallahi MJ. TB and the COVID-19 pandemic: brothers in arms against lung health. *Int J Tuberc Lung Dis.* 2020;24(10):1126–7, <http://dx.doi.org/10.5588/ijtld.20.0449>.
99. Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. *Int J Tuberc Lung Dis.* 2020;24(9):981–2, <http://dx.doi.org/10.5588/ijtld.20.0418>.
100. Wilson FA, Miller TL, Stimpson JP. COVID-19 and TB control in immigrant communities. *Int J Tuberc Lung Dis.* 2020;24(9):975–7, <http://dx.doi.org/10.5588/ijtld.20.0456>.
101. van der Zalm MM, Lishman J, Verhagen LM, Redfern A, Smit L, Barday M, et al. Clinical experience with SARS CoV-2 related illness in children - hospital experience in Cape Town, South Africa. *Clin Infect Dis.* 2020, <http://dx.doi.org/10.1093/cid/ciaa1666>, ciaa1666.
102. Min J, Kim HW, Koo HK, Ko Y, Oh JY, Kim J, et al. Impact of COVID-19 Pandemic on the National PPM Tuberculosis Control Project in Korea: the Korean PPM Monitoring Database between July 2019 and June 2020. *J Korean Med Sci.* 2020;35(43):e388, <http://dx.doi.org/10.3346/jkms.2020.35.e388>.